TY - JOUR
T1 - Treatment of refractory necrobiotic xanthogranulomas with extracorporeal photopheresis and intravenous immunoglobulin
AU - Liszewski, Walter Joseph
AU - Wisniewski, Joy D.
AU - Safah, Hana
AU - Boh, Erin E.
N1 - Publisher Copyright:
© 2014 Wiley Periodicals, Inc.
PY - 2014/9/1
Y1 - 2014/9/1
N2 - Necrobiotic xanthogranuloma (NXG) is a disease of fibrotic or telangiectatic granulomatous papules and nodules that can ultimately progress into ulcerated plaques. Although the exact cause of NXG is unknown, it most often occurs in patients with paraproteinemia secondary to a hematologic disease. Consequently, therapy for NXG is targeted at treating the underlying hematologic disease, and subsequent paraproteinemia, with alkylating agents, antimetabolites, radiation, and/or immunosuppressive agents. Cases refractory to these therapies often have poor outcomes. We report the successful treatment of two patients with refractory NXG with two different modalities: extracorporeal photopheresis (ECP) and intravenous immunoglobulin (IVIG). The first case shows a patient without paraproteinemia who had success with ECP and IVIG, and the second is a patient with paraproteinemia treated effectively with IVIG. The beneficial response of our patients to IVIG, as well as ECP, shows that they may be an effective treatment option for refractory NXG.
AB - Necrobiotic xanthogranuloma (NXG) is a disease of fibrotic or telangiectatic granulomatous papules and nodules that can ultimately progress into ulcerated plaques. Although the exact cause of NXG is unknown, it most often occurs in patients with paraproteinemia secondary to a hematologic disease. Consequently, therapy for NXG is targeted at treating the underlying hematologic disease, and subsequent paraproteinemia, with alkylating agents, antimetabolites, radiation, and/or immunosuppressive agents. Cases refractory to these therapies often have poor outcomes. We report the successful treatment of two patients with refractory NXG with two different modalities: extracorporeal photopheresis (ECP) and intravenous immunoglobulin (IVIG). The first case shows a patient without paraproteinemia who had success with ECP and IVIG, and the second is a patient with paraproteinemia treated effectively with IVIG. The beneficial response of our patients to IVIG, as well as ECP, shows that they may be an effective treatment option for refractory NXG.
KW - Extracorporeal photopheresis
KW - Intravenous immunoglobulin
KW - Necrobiotic xanthogranuloma
UR - http://www.scopus.com/inward/record.url?scp=84907854391&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907854391&partnerID=8YFLogxK
U2 - 10.1111/dth.12135
DO - 10.1111/dth.12135
M3 - Article
C2 - 24910296
AN - SCOPUS:84907854391
SN - 1396-0296
VL - 27
SP - 268
EP - 271
JO - Dermatologic Therapy
JF - Dermatologic Therapy
IS - 5
ER -